<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35275317</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1590-3478</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>43</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title>
          <ISOAbbreviation>Neurol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Central nervous system adverse events after ChAdOx1 vaccination.</ArticleTitle>
        <Pagination>
          <StartPage>3503</StartPage>
          <EndPage>3507</EndPage>
          <MedlinePgn>3503-3507</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-022-06000-3</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Post-ChAdOx1 vaccine (AZD1222) adverse events following immunization (AEFI) are uncommon. Recently described neurological events include thrombocytopenia with thrombosis syndrome (TTS) with cerebral venous thrombosis and Guillain-Barré syndrome. There are very few AEFI reports following COVID vaccination from India, because of underreporting or other factors. A few cases of acute transverse myelitis (ATM) and post-vaccinal encephalitis have also been reported.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Over 11 months, in 2 districts of Kerala, India, 8.19 million people were vaccinated with the ChAdOx1 vaccine.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">During this period, we encountered five cases of autoimmune central nervous system (CNS) AEFI following ChAdOX1 (Oxford/AstraZeneca, Covishield™) vaccination. These included three cases of acute disseminated encephalomyelitis (ADEM), one case of opsoclonus myoclonus ataxia syndrome (OMAS), and one case of limbic encephalitis. The calculated crude incidence of post-ChAdOX1 autoimmune CNS AEFI was approximately 0.24 cases per million for encephalitis and 0.36 per million for ADEM. This was compared to the crude annual incidence of community-acquired ADEM worldwide (3.2-4 per million) and the crude annual incidence of community-acquired encephalitis in India (8.35-10 per million).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There was no increase in the incidence of post-vaccination CNS AEFI (ADEM or encephalitis) as compared to the community incidence of ADEM or encephalitis. While this emphasizes the safety of ChAdOX1 nCoV-19 vaccination for COVID-19, it is important to recognize these post-vaccination autoimmune syndromes early to initiate immunosuppressive therapy.</AbstractText>
          <CopyrightInformation>© 2022. Fondazione Società Italiana di Neurologia.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Maramattom</LastName>
            <ForeName>Boby Varkey</ForeName>
            <Initials>BV</Initials>
            <Identifier Source="ORCID">0000-0001-7032-4412</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Aster Medcity, Kochi, Kerala, India. bobvarkey@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lotlikar</LastName>
            <ForeName>Radhika Sanjay</ForeName>
            <Initials>RS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Sree Chitra Tirunal Institute of Medical Sciences, Thiruvananthapuram, Kerala, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sukumaran</LastName>
            <ForeName>Sajith</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Sree Chitra Tirunal Institute of Medical Sciences, Thiruvananthapuram, Kerala, India.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Neurol Sci</MedlineTA>
        <NlmUniqueID>100959175</NlmUniqueID>
        <ISSNLinking>1590-1874</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014612">Vaccines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>B5S3K2V0G8</RegistryNumber>
          <NameOfSubstance UI="D000090985">ChAdOx1 nCoV-19</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000090985" MajorTopicYN="N">ChAdOx1 nCoV-19</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004660" MajorTopicYN="Y">Encephalitis</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004673" MajorTopicYN="Y">Encephalomyelitis, Acute Disseminated</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053578" MajorTopicYN="Y">Opsoclonus-Myoclonus Syndrome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014612" MajorTopicYN="Y">Vaccines</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ChAdOX1 nCoV-19 vaccination and encephalitis</Keyword>
        <Keyword MajorTopicYN="N">ChAdOX1 nCoV-19 vaccination and myelitis</Keyword>
        <Keyword MajorTopicYN="N">Post-vaccination neurological events</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>11</Day>
          <Hour>12</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35275317</ArticleId>
        <ArticleId IdType="pmc">PMC8913322</ArticleId>
        <ArticleId IdType="doi">10.1007/s10072-022-06000-3</ArticleId>
        <ArticleId IdType="pii">10.1007/s10072-022-06000-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S (2021) Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 384(22)</Citation>
        </Reference>
        <Reference>
          <Citation>Maramattom BV, Krishnan P, Paul R, Padmanabhan S, Cherukudal VNS, Syed AA, et al.  Guillain-Barré syndrome following ChAdOx1-S/nCoV-19 vaccine. Ann Neurol. 2021;90(2):312–314. doi: 10.1002/ana.26143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.26143</ArticleId>
            <ArticleId IdType="pubmed">34114256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuhorn F, Graf T, Klingebiel R, Schäbitz WR, Rogalewski A (2021) Postvaccinal encephalitis after ChAdOx1 nCov-19. Ann Neurol [Internet]. 2021 Jul 29 [cited 2021 Aug 5];</Citation>
        </Reference>
        <Reference>
          <Citation>Sejvar JJ, Kohl KS, Bilynsky R, Blumberg D, Cvetkovich T, Galama J, et al (2007) Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine [Internet]. 2007 [cited 2021 Aug 3];25:5771–92.</Citation>
        </Reference>
        <Reference>
          <Citation>Roser M, Ritchie H, Ortiz-Ospina E, Hasell J (2020) Coronavirus (COVID-19) deaths - statistics and research - our world in data [Internet]. Our world in data. 2020 [cited 2021 Nov 11]. Available from: https://ourworldindata.org/covid-vaccinations?country=OWID_WRL</Citation>
        </Reference>
        <Reference>
          <Citation>Chen Y, Ma F, Xu Y, Chu X, Zhang J. Incidence of acute disseminated encephalomyelitis in the Jiangsu province of China, 2008–2011. Mult Scler J - Exp Transl Clin [Internet] 2015;1:205521731559483.</Citation>
        </Reference>
        <Reference>
          <Citation>Singh AK, Kumar A, Dhole TN 2020 Recent trends and changing aetiology of acute encephalitis syndrome in India. Asian J Res Infect Dis [Internet]. 33–47.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35275317</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1590-3478</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>43</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title>
          <ISOAbbreviation>Neurol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Central nervous system adverse events after ChAdOx1 vaccination.</ArticleTitle>
        <Pagination>
          <StartPage>3503</StartPage>
          <EndPage>3507</EndPage>
          <MedlinePgn>3503-3507</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-022-06000-3</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Post-ChAdOx1 vaccine (AZD1222) adverse events following immunization (AEFI) are uncommon. Recently described neurological events include thrombocytopenia with thrombosis syndrome (TTS) with cerebral venous thrombosis and Guillain-Barré syndrome. There are very few AEFI reports following COVID vaccination from India, because of underreporting or other factors. A few cases of acute transverse myelitis (ATM) and post-vaccinal encephalitis have also been reported.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Over 11 months, in 2 districts of Kerala, India, 8.19 million people were vaccinated with the ChAdOx1 vaccine.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">During this period, we encountered five cases of autoimmune central nervous system (CNS) AEFI following ChAdOX1 (Oxford/AstraZeneca, Covishield™) vaccination. These included three cases of acute disseminated encephalomyelitis (ADEM), one case of opsoclonus myoclonus ataxia syndrome (OMAS), and one case of limbic encephalitis. The calculated crude incidence of post-ChAdOX1 autoimmune CNS AEFI was approximately 0.24 cases per million for encephalitis and 0.36 per million for ADEM. This was compared to the crude annual incidence of community-acquired ADEM worldwide (3.2-4 per million) and the crude annual incidence of community-acquired encephalitis in India (8.35-10 per million).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There was no increase in the incidence of post-vaccination CNS AEFI (ADEM or encephalitis) as compared to the community incidence of ADEM or encephalitis. While this emphasizes the safety of ChAdOX1 nCoV-19 vaccination for COVID-19, it is important to recognize these post-vaccination autoimmune syndromes early to initiate immunosuppressive therapy.</AbstractText>
          <CopyrightInformation>© 2022. Fondazione Società Italiana di Neurologia.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Maramattom</LastName>
            <ForeName>Boby Varkey</ForeName>
            <Initials>BV</Initials>
            <Identifier Source="ORCID">0000-0001-7032-4412</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Aster Medcity, Kochi, Kerala, India. bobvarkey@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lotlikar</LastName>
            <ForeName>Radhika Sanjay</ForeName>
            <Initials>RS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Sree Chitra Tirunal Institute of Medical Sciences, Thiruvananthapuram, Kerala, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sukumaran</LastName>
            <ForeName>Sajith</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Sree Chitra Tirunal Institute of Medical Sciences, Thiruvananthapuram, Kerala, India.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Neurol Sci</MedlineTA>
        <NlmUniqueID>100959175</NlmUniqueID>
        <ISSNLinking>1590-1874</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014612">Vaccines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>B5S3K2V0G8</RegistryNumber>
          <NameOfSubstance UI="D000090985">ChAdOx1 nCoV-19</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000090985" MajorTopicYN="N">ChAdOx1 nCoV-19</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004660" MajorTopicYN="Y">Encephalitis</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004673" MajorTopicYN="Y">Encephalomyelitis, Acute Disseminated</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053578" MajorTopicYN="Y">Opsoclonus-Myoclonus Syndrome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014612" MajorTopicYN="Y">Vaccines</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ChAdOX1 nCoV-19 vaccination and encephalitis</Keyword>
        <Keyword MajorTopicYN="N">ChAdOX1 nCoV-19 vaccination and myelitis</Keyword>
        <Keyword MajorTopicYN="N">Post-vaccination neurological events</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>11</Day>
          <Hour>12</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35275317</ArticleId>
        <ArticleId IdType="pmc">PMC8913322</ArticleId>
        <ArticleId IdType="doi">10.1007/s10072-022-06000-3</ArticleId>
        <ArticleId IdType="pii">10.1007/s10072-022-06000-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S (2021) Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 384(22)</Citation>
        </Reference>
        <Reference>
          <Citation>Maramattom BV, Krishnan P, Paul R, Padmanabhan S, Cherukudal VNS, Syed AA, et al.  Guillain-Barré syndrome following ChAdOx1-S/nCoV-19 vaccine. Ann Neurol. 2021;90(2):312–314. doi: 10.1002/ana.26143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.26143</ArticleId>
            <ArticleId IdType="pubmed">34114256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuhorn F, Graf T, Klingebiel R, Schäbitz WR, Rogalewski A (2021) Postvaccinal encephalitis after ChAdOx1 nCov-19. Ann Neurol [Internet]. 2021 Jul 29 [cited 2021 Aug 5];</Citation>
        </Reference>
        <Reference>
          <Citation>Sejvar JJ, Kohl KS, Bilynsky R, Blumberg D, Cvetkovich T, Galama J, et al (2007) Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine [Internet]. 2007 [cited 2021 Aug 3];25:5771–92.</Citation>
        </Reference>
        <Reference>
          <Citation>Roser M, Ritchie H, Ortiz-Ospina E, Hasell J (2020) Coronavirus (COVID-19) deaths - statistics and research - our world in data [Internet]. Our world in data. 2020 [cited 2021 Nov 11]. Available from: https://ourworldindata.org/covid-vaccinations?country=OWID_WRL</Citation>
        </Reference>
        <Reference>
          <Citation>Chen Y, Ma F, Xu Y, Chu X, Zhang J. Incidence of acute disseminated encephalomyelitis in the Jiangsu province of China, 2008–2011. Mult Scler J - Exp Transl Clin [Internet] 2015;1:205521731559483.</Citation>
        </Reference>
        <Reference>
          <Citation>Singh AK, Kumar A, Dhole TN 2020 Recent trends and changing aetiology of acute encephalitis syndrome in India. Asian J Res Infect Dis [Internet]. 33–47.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
